Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eton Pharmaceuticals filings document a rare-disease pharmaceutical business built around approved products, licensed commercialization rights and late-stage product candidates. Recent 8-K reports cover DESMODA FDA approval for central diabetes insipidus, the HEMANGEOL U.S. rights acquisition and launch, ET-700 clinical study disclosure for Wilson disease, and quarterly and annual financial results that include GAAP and non-GAAP measures.
The filing record also includes credit-agreement amendments, direct financial obligation disclosures, executive appointment and compensation matters, and definitive proxy materials covering executive compensation, equity awards and governance matters. These filings tie product portfolio changes, financing terms, capital structure and corporate governance to Eton's public-company reporting.
Eton Pharmaceuticals’ Chief Business Officer reported routine equity compensation and related share withholding. On 12/11/2025, the officer was awarded 5,300 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock, and the RSUs vest immediately as of the award date.
On 12/12/2025, 6,264 shares of common stock were disposed of under transaction code F, with a reported price of $17, in connection with shares withheld by the issuer to satisfy withholding taxes upon RSU vesting. These shares were sold in multiple trades at prices ranging from $16.83 to $17.11, and the reported price reflects the weighted average sales price. After these transactions, the officer directly beneficially owns 632,180 shares of common stock and 638,468 RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported changes in his equity holdings. On 12/11/2025, he received 5,502 restricted stock units, each representing one share of common stock, which vested immediately and increased his total restricted stock unit holdings to 210,255. On 12/12/2025, 4,542 common shares were disposed of in a transaction coded “F” at a weighted average price of $16.99 per share, with shares withheld to satisfy tax obligations and sold in multiple trades between $16.94 and $17.07. After these transactions, he directly owned 215,713 shares of Eton common stock.
Eton Pharmaceuticals, Inc. reported an insider stock transaction by a person who serves as its President & CEO, director, and 10% owner. On 12/12/2025, 6,732 shares of common stock were disposed of in a transaction coded "F," which reflects shares withheld by the company to cover withholding taxes upon the vesting of restricted stock units. The shares were sold at a weighted average price of $16.83.
Following this tax-related transaction, the reporting person directly beneficially owns 2,894,281 shares of Eton Pharmaceuticals common stock.
Eton Pharmaceuticals filed a Form S-8 to register 1,068,363 additional shares of common stock under its 2018 Equity Incentive Plan and 150,000 additional shares under its 2018 Employee Stock Purchase Plan. These shares expand the pool available for employee equity awards and stock purchases, supporting compensation and retention programs. The company notes it previously registered 7,699,634 shares under the 2018 Equity Incentive Plan and 1,050,000 shares under the 2018 ESPP on earlier Form S-8 filings, and incorporates its latest Annual Report, Quarterly Reports, and specified Current Reports by reference.
Eton Pharmaceuticals, Inc. filed an amended Form 8-K to add required financial information related to its completed acquisition of the Increlex® product rights from Ipsen S.A. The amendment supplies audited abbreviated financial statements for INCRELEX as of and for the years ended December 31, 2022 and 2023, along with unaudited abbreviated financial statements as of September 30, 2024 and for the nine months ended September 30, 2023 and 2024. It also includes unaudited pro forma condensed combined financial statements for Eton and INCRELEX for the nine-month periods ended September 30, 2023 and 2024, helping readers see how the acquisition would have affected the company’s historical financials. Other disclosures in the original report remain unchanged.
Eton Pharmaceuticals reported third‑quarter results. Net revenues were $22.459 million, driven by product sales and royalties. Gross profit reached $7.855 million. The quarter recorded a net loss of $1.927 million, or $0.07 per share. For the nine months, net revenues were $58.669 million with a net loss of $6.084 million.
Cash and cash equivalents were $37.121 million as of September 30, 2025, up from $14.936 million at year‑end, supported by $22.075 million in operating cash flow year‑to‑date. Current liabilities rose to $44.183 million, including higher accounts payable and Medicaid rebate accruals, and long‑term debt stood at $27.591 million. Customer concentration remains significant: AnovoRx represented 85.8% of net product revenues for the nine months and 65.8% of net accounts receivable as of September 30, 2025. The company also recorded intangible amortization tied to recent product acquisitions and recognized partial licensing revenue with Esteve related to INCRELEX.
Eton Pharmaceuticals furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1. The filing also discusses the use of non-GAAP Adjusted EBITDA, which management uses for planning, evaluating performance, communicating with the board and investors, and assessing acquisitions and comparative net sales. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference.
Eton Pharmaceuticals CFO James R. Gruber reported sales of company stock on August 19 and August 20, 2025. The Form 4 shows he sold 39,082 shares on 08/19/2025 at a weighted average price of $16.16 and 2,631 shares on 08/20/2025 at a weighted average price of $16.02, for total shares sold of 41,713. Following those transactions his beneficial ownership is reported as 205,299 shares after the 08/19 trade and 204,753 shares after the 08/20 trade, held directly. The filing is signed and dated 08/20/2025 and includes an explanation that trade details by price are available on request.
Eton Pharmaceuticals filed a Form 144 notifying the proposed sale of 41,713 shares of its common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $692,645 and an approximate sale date of 08/18/2025. The notice lists the securities' acquisition history: seven lots acquired between 12/09/2022 and 12/10/2024 via ESPP payroll purchases and company grants, totaling the units shown. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.